RxSight, Inc. (NASDAQ:RXST) Position Increased by Renaissance Technologies LLC

Renaissance Technologies LLC lifted its stake in RxSight, Inc. (NASDAQ:RXST - Free Report) by 102.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 361,500 shares of the company's stock after buying an additional 183,300 shares during the period. Renaissance Technologies LLC owned approximately 0.90% of RxSight worth $12,428,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Legal & General Group Plc boosted its holdings in RxSight by 1.2% in the 4th quarter. Legal & General Group Plc now owns 42,445 shares of the company's stock worth $1,459,000 after acquiring an additional 512 shares during the period. Wells Fargo & Company MN boosted its stake in shares of RxSight by 1.7% in the fourth quarter. Wells Fargo & Company MN now owns 26,574 shares of the company's stock valued at $914,000 after purchasing an additional 445 shares during the period. Resona Asset Management Co. Ltd. acquired a new stake in RxSight during the 4th quarter valued at $385,000. DF Dent & Co. Inc. acquired a new stake in RxSight during the 4th quarter valued at $14,524,000. Finally, ExodusPoint Capital Management LP lifted its holdings in RxSight by 36.5% in the 4th quarter. ExodusPoint Capital Management LP now owns 24,417 shares of the company's stock worth $839,000 after buying an additional 6,534 shares in the last quarter. Institutional investors and hedge funds own 78.78% of the company's stock.

Insider Buying and Selling

In other RxSight news, Director Shweta Maniar sold 3,519 shares of RxSight stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $30.87, for a total transaction of $108,631.53. Following the transaction, the director now directly owns 7,383 shares in the company, valued at approximately $227,913.21. The trade was a 32.28 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Tamara Fountain sold 7,000 shares of the stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $25.71, for a total value of $179,970.00. Following the completion of the sale, the director now owns 24,793 shares of the company's stock, valued at $637,428.03. The trade was a 22.02 % decrease in their position. The disclosure for this sale can be found here. Insiders own 9.36% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on RXST. Needham & Company LLC reaffirmed a "buy" rating and set a $43.00 target price on shares of RxSight in a research report on Thursday, April 3rd. Piper Sandler initiated coverage on RxSight in a report on Tuesday, April 15th. They set a "neutral" rating and a $18.00 price objective on the stock. UBS Group downgraded shares of RxSight from a "buy" rating to a "neutral" rating and decreased their price target for the stock from $45.00 to $16.00 in a research report on Wednesday, April 9th. Wells Fargo & Company reduced their price objective on shares of RxSight from $35.00 to $22.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 3rd. Finally, Bank of America reissued an "underperform" rating and issued a $22.00 target price (down previously from $36.00) on shares of RxSight in a research report on Thursday, April 3rd. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $37.60.

RxSight Trading Down 0.6 %

RXST stock traded down $0.09 during trading hours on Friday, hitting $14.43. 1,068,889 shares of the stock traded hands, compared to its average volume of 618,522. The stock has a 50-day simple moving average of $23.77 and a 200 day simple moving average of $35.05. The company has a market cap of $584.29 million, a P/E ratio of -17.39 and a beta of 1.26. RxSight, Inc. has a one year low of $13.50 and a one year high of $66.54.

RxSight (NASDAQ:RXST - Get Free Report) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.25). The business had revenue of $40.21 million during the quarter, compared to analyst estimates of $40.23 million. RxSight had a negative return on equity of 14.00% and a negative net margin of 23.92%. Analysts forecast that RxSight, Inc. will post -0.7 earnings per share for the current year.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.